Prices are updated after-hours
  Antibody

nasdaq:ABCZF Abcam plc

ABCZF | $22.1 -2.32% 4K twitter stocktwits trandingview |
Health Technology
(0.0% 1d) (0.0% 1m) (43.5% 1y) (0.0% 2d) (0.0% 3d) (0.0% 7d) (1011.11% volume)
Earnings Calendar:
Market Cap: $ 5,484,184,018
http://abcam.com
 Sec Filling | Patents | n/a employees


(GB) Abcam Plc distributes antibodies and associated protein research tools. Its product includes primary and secondary antibodies, proteins, peptides, lysates, biochemicals, immunoassays and other kits. The company was founded by Adam Robert David Cleevely, Anthony Kouzarides and Jonathan Milner on February 12, 1998 and is headquartered in Cambridge, the United Kingdom.
antibody  

add to watch list Paper trade email alert is off

nasdaq:GLPGF GALAPAGOS NV

GLPGF | News | $35.5157 71.75% 4.8K twitter stocktwits trandingview |
Health Technology
(0.0% 1d) (0.0% 1m) (-6.5% 1y) (0.0% 2d) (0.0% 3d) (0.0% 7d) (240500.0% volume)
Earnings Calendar:
Market Cap: $ 2,274,107,918
http://www.glpg.com
 Sec Filling | Patents | n/a employees


(BE) Galapagos NV is a biotechnology company, which engages in the identification and development of small molecule and antibody therapies. It operates through the Research & Development and Fee-for-Services segment. The company was founded by Onno van de Stolpe, Rudi Pauwels, and Helmuth van Es on June 30, 1999 and is headquartered in Mechelen, Belgium.
antibody   3d  

add to watch list Paper trade email alert is off

nasdaq:MPSYF MorphoSys AG

MPSYF | News | $70.28 -71.33% 110 twitter stocktwits trandingview |
Health Technology
(0.0% 1d) (0.0% 1m) (154.6% 1y) (0.0% 2d) (0.0% 3d) (0.0% 7d) (223918.67% volume)
Earnings Calendar:
Market Cap: $ 2,583,142,384
http://www.morphosys.de
 Sec Filling | Patents | n/a employees


(DE) MorphoSys AG engages in the development of antibodies for therapeutic, diagnostics, and research applications. It operates through the Proprietary Development and Partnered Discovery segments. The Proprietary Development segment combines proprietary research and development of therapeutic compounds. The Partnered Discovery segment offers technologies to make human antibody-based therapeutics on behalf of partners in the pharmaceutical industry. The company was founded by Andreas Pluckthun and Simon E. Moroney in July 1992 and is headquartered in Planegg, Germany.
diagnostics   antibody  

add to watch list Paper trade email alert is off

nasdaq:FSTX F-star Therapeutics Inc.

FSTX | $7.12 0.0% 0 twitter stocktwits trandingview |
Health Technology
(0.0% 1d) (0.0% 1m) (0.0% 1y) (0.0% 2d) (0.0% 3d) (0.0% 7d) (-100.0% volume)
Earnings Calendar: 2023-03-14
Market Cap: $ 156,511,263
http://www.f-star.com
 Sec Filling | Patents | 30 employees


(US) F-star Therapeutics, Inc. is a clinical-stage immuno-oncology company. It focuses on transforming the lives of patients with cancer through the development of tetravalent mAb2 bispecific antibodies. The firm’s product candidate, FS118, simultaneously targets two immune checkpoint receptors, LAG-3 and PD-L1, to directly address known tumor evasion pathways. The company is headquartered in Cambridge, the United Kingdom.
cancer   antibody  

add to watch list Paper trade email alert is off

Ambrx Biopharma Inc - ADR

AMAM 4 | $28.0 0.0% 1.4M twitter stocktwits trandingview |
Professional, Scientific, and T...
(0.0% 1d) (0.0% 1m) (139.3% 1y) (0.0% 2d) (0.0% 3d) (0.0% 7d) (117.58% volume)
Earnings Calendar:
Market Cap: $ 1,768,206,832
https://ambrx.com
 Sec Filling | Patents | n/a employees


Ambrx is a clinical stage biopharmaceutical company using an expanded genetic code technology platform to discover and develop Engineered Precision Biologics. These include next generation antibody drug conjugates (ADCs), bispecifics, targeted immuno-oncology therapies, novel cytokines to modulate the immune system, and long-acting therapeutic peptides for metabolic and cardiovascular disease. Ambrx is advancing a robust portfolio of clinical and preclinical programs designed to optimize efficacy, safety and ease of use, in multiple therapeutic areas, including its lead product candidate ARX788. In addition, the company has clinical collaborations with Bristol Myers Squibb, Astellas, BeiGene, Sino Biopharma, Elanco and NovoCodex, for drug candidates generated using Ambrx technology.
urea   antibody   genetic   cardiovascular   optical   metabolic  

add to watch list Paper trade email alert is off

nyse:NHWK NightHawk Biosciences Inc

NHWK | $0.4135 0.0% 170K twitter stocktwits trandingview |
Manufacturing
(0.0% 1d) (0.0% 1m) (-47.8% 1y) (0.0% 2d) (0.0% 3d) (0.0% 7d) (NaN% volume)
Earnings Calendar:
Market Cap: $ 10,784,862
https://www.heatbio.com
 Sec Filling | Patents | 39 employees


(US) Heat Biologics is a biopharmaceutical company focused on developing first-in-class therapies to modulate the immune system. The company's gp96 platform is designed to activate immune responses against cancer or infectious diseases. The Company has multiple product candidates in development leveraging the gp96 platform, including HS-110, which has completed enrollment in its Phase 2 trial, and a COVID-19 vaccine program in preclinical development. In addition, Heat Biologics is also developing a pipeline of proprietary immunomodulatory antibodies and cell-based therapies, including PTX-35 and HS-130 in Phase 1 clinical trials.
antibody   vaccine   infectious disease   cancer   t-cell   covid   hepatitis  

add to watch list Paper trade email alert is off

nasdaq:CFRX ContraFect Corporation

CFRX | $0.05 0.0% 910K twitter stocktwits trandingview |
Health Technology
(0.0% 1d) (0.0% 1m) (-97.5% 1y) (0.0% 2d) (0.0% 3d) (0.0% 7d) (2396.14% volume)
Earnings Calendar: 2022-11-14
Market Cap: $ 535,240
http://www.contrafect.com
 Sec Filling | Patents | 24 employees


(US) ContraFect Corp. is a clinical stage biotechnology company, which engages in discovering and developing therapeutic protein and antibody products for the treatment of life-threatening infectious diseases. Its pipeline consists of CF-301, a bacteriophage-derived lysin with potent activity against Staphylococcus aureus bloodstream infections; and CF-404, which composed of three fully human monoclonal antibodies designed to treat all seasonal strains of human influenza. The company was founded by Robert Nowinski on March 5, 2008 and is headquartered in Yonkers, NY.
antibody   monoclonal antibodies   infectious disease   influenza   treatment   bloodstream   injection  

add to watch list Paper trade email alert is off

nasdaq:ABCM Abcam plc

ABCM | $23.99 0.0% 7.4M twitter stocktwits trandingview |
Health Technology
(0.0% 1d) (0.0% 1m) (53.4% 1y) (0.0% 2d) (0.0% 3d) (0.1% 7d) (NaN% volume)
Earnings Calendar:
Market Cap: $ 5,500,233,049
http://abcam.com
 Sec Filling | Patents | 1500 employees


Abcam Plc distributes antibodies and associated protein research tools. Its product includes primary and secondary antibodies, proteins, peptides, lysates, biochemicals, immunoassays and other kits. The company was founded by Adam Robert David Cleevely, Anthony Kouzarides and Jonathan Milner on February 12, 1998 and is headquartered in Cambridge, the United Kingdom.
antibody  

add to watch list Paper trade email alert is off

nasdaq:VIVO Meridian Bioscience Inc.

VIVO | $33.97 0.0% 0 twitter stocktwits trandingview |
Health Technology
(0.0% 1d) (0.0% 1m) (0.0% 1y) (0.0% 2d) (0.7% 3d) (0.0% 7d) (Infinity% volume)
Earnings Calendar: 2023-02-03
Market Cap: $ 1,488,831,011
http://www.meridianbioscience.com
 Sec Filling | Patents | 750 employees


(US) Meridian Bioscience, Inc. engages in the development, manufacture, sale, and distribution of diagnostic test kits, antigens, reagents, and related products. It operates through the following segments: Diagnostics and Life Science. The Diagnostics segment consists testing platforms and technologies such as Isothermal DNA Amplification, Rapid Immunoassay, Enzyme-linked Immunoassay, and Anodic Stripping Voltammetry. The Life Science segment distributes bulk antigens, antibodies, PCR/qPCR reagents, nucleotides, competent cells, and bioresearch reagents used by researchers, agri-bio companies, and other diagnostic manufacturing companies. The company was founded by William J. Motto in 1976 and is headquartered in Cincinnati, OH.
antibody   t-cell   diagnostics   ceiling  

add to watch list Paper trade email alert is off

nasdaq:IMGN ImmunoGen, Inc.

IMGN | $31.23 0.03% 49M twitter stocktwits trandingview |
Health Technology
(0.0% 1d) (0.0% 1m) (652.8% 1y) (0.0% 2d) (0.0% 3d) (0.0% 7d) (-100.0% volume)
Earnings Calendar: 2024-02-29
Market Cap: $ 8,315,433,277
http://www.immunogen.com
 Sec Filling | Patents | 75 employees


(US) ImmunoGen, Inc. engages in the discovery and development of antibody-drug conjugates to improve outcomes for cancer patients. Its pipeline includes Mirvetuximab Soravtansine, IMGN632, IMGC936, and IMGN151. The company was founded in March 1981 and is headquartered in Waltham, MA.
cancer   antibody  

add to watch list Paper trade email alert is off

nyse:ADCT ADC Therapeutics SA

ADCT | $4.72 -0.84% 0.0% 320K twitter stocktwits trandingview |
Health Technology
(0.0% 1d) (0.6% 1m) (113.5% 1y) (0.0% 2d) (0.0% 3d) (8.9% 7d) (131.93% volume)
Earnings Calendar:
Market Cap: $ 390,882,080
http://www.adctherapeutics.com
 Sec Filling | Patents | 127 employees


ADC Therapeutics SA is a clinical-stage biotechnology company, which engages in the research and development and commercialization of targeted antibody drug conjugates for patients with hematological malignancies and solid tumors. Its products include loncastuximab tesirine, camidanlumab tesirine, and ADCT-602. The company was founded by Christopher Martin on June 6, 2011 and is headquartered in Epalinges, Switzerland.
antibody  

add to watch list Paper trade email alert is off

nasdaq:XFOR X4 Pharmaceuticals, Inc.

XFOR | $1.255 4.58% 4.38% 3M twitter stocktwits trandingview |
Health Technology
(0.0% 1d) (17.6% 1m) (-11.8% 1y) (0.0% 2d) (0.0% 3d) (-4.0% 7d) (17.08% volume)
Earnings Calendar: 2024-03-26
Market Cap: $ 210,761,915
http://www.x4pharma.com
 Sec Filling | Patents | 58 employees


(US) X4 Pharmaceuticals, Inc. operates as a biotechnology company, which engages in developing human antibodies for treating infectious diseases. The company focuses on restoring healthy immune system function by developing novel therapeutics for the treatment of rare diseases. Its products in pipeline include X4P-001, X4P-002, and X4P-003. The company was founded by Henri A. Termeer, Keith T. Flaherty, Renato T. Skerlj, Richard Peters and Paula Ragan and is headquartered in Cambridge, MA.
antibody   infectious disease   msa   treatment  

add to watch list Paper trade email alert is off

nasdaq:ABCL AbCellera Biologics Inc

ABCL | $3.88 -0.77% -0.77% 980K twitter stocktwits trandingview |

(0.0% 1d) (-14.4% 1m) (-43.1% 1y) (0.0% 2d) (0.0% 3d) (-3.1% 7d) (-6.4% volume)
Earnings Calendar: 2024-02-20
Market Cap: $ 1,135,994,750
https://www.abcellera.com
 Sec Filling | Patents | 206 employees


(CA) AbCellera is a technology company that searches, decodes, and analyzes natural immune systems to find antibodies that its partners can develop into drugs to prevent and treat disease. AbCellera partners with drug developers of all sizes, from large pharmaceutical to small biotechnology companies, empowering them to move quickly, reduce cost, and tackle the toughest problems in drug development.
drug discovery   education   antibody  

add to watch list Paper trade email alert is off

nyse:ZYME Zymeworks Inc.

ZYME | $8.85 2.08% 2.03% 550K twitter stocktwits trandingview |
Health Technology
(0.0% 1d) (-17.7% 1m) (-10.0% 1y) (0.0% 2d) (0.0% 3d) (-2.6% 7d) (-5.44% volume)
Earnings Calendar: 2024-03-06
Market Cap: $ 624,528,765
http://www.zymeworks.com
 Sec Filling | Patents | 256 employees


(CA) Zymeworks, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovery, development and commercialization of biotherapeutics. Its product, ZW25 and ZW49 are a bispecific antibody that cans two non-overlapping epitopes. The company was founded by Anthony Fejes, J. Haig deB Farris, Nick Bedford, Ali Tehrani and Andrew S. Wright on September 8, 2003 and is headquartered in Vancouver, Canada.
antibody   urea  

add to watch list Paper trade email alert is off

nasdaq:VIR Vir Biotechnology, Inc.

VIR | $7.96 0.0% 1.1M twitter stocktwits trandingview |
Health Technology
(0.0% 1d) (-18.9% 1m) (-66.7% 1y) (0.0% 2d) (0.0% 3d) (-3.7% 7d) (16.86% volume)
Earnings Calendar: 2024-02-22
Market Cap: $ 1,070,620,000
http://www.vir.bio
 Sec Filling | Patents | 229 employees


Vir Biotechnology, Inc. operates as a clinical-stage immunology company that focuses on combining immunologic insights with cutting-edge technologies to treat and prevent serious infectious diseases. The firm's technology platforms include antibody, T cell, innate immunity and siRNA, which are designed to stimulate and enhance the immune system by exploiting critical observations of natural immune processes. The company was founded by Robert Taylor Nelsen, Klaus Frueh, Jay Parrish, Lawrence Corey, and Louis Picker in April 7, 2016 and is headquartered in San Francisco, CA.
antibody   infectious disease   immunology   t-cell   msa   ceiling  

add to watch list Paper trade email alert is off

nasdaq:YMAB Y-mAbs Therapeutics, Inc.

YMAB | $15.15 1.0% 0.99% 470K twitter stocktwits trandingview |
Health Technology
(0.0% 1d) (-2.5% 1m) (159.6% 1y) (0.0% 2d) (0.0% 3d) (1.3% 7d) (1.89% volume)
Earnings Calendar: 2024-02-29
Market Cap: $ 663,223,141
http://www.ymabs.com
 Sec Filling | Patents | 65 employees


Y-mAbs Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on the development and commercialization of antibody-based therapeutic products for the treatment of cancer. Its services include discovery, protein engineering, clinical and regulatory. Y-mAbs Therapeutics was founded by Thomas Gad in April 2015 and is headquartered in New York, NY.
cancer   antibody   treatment  

Drugs
DANYELZA (Naxitamab)

add to watch list Paper trade email alert is off

nasdaq:VRDN Viridian Therapeutics Inc

VRDN | $14.59 -3.76% -3.91% 1.5M twitter stocktwits trandingview |
Health Care and Social Assistan...
(0.0% 1d) (-16.2% 1m) (-47.3% 1y) (0.0% 2d) (0.5% 3d) (-3.1% 7d) (-12.21% volume)
Earnings Calendar: 2024-03-07
Market Cap: $ 915,778,846
http://www.miragen.com/
 Sec Filling | Patents | 27 employees


(US) Viridian Therapeutics is a biotechnology company advancing new treatments for patients suffering from serious diseases but underserved by today’s therapies. Viridian’s most advanced program, VRDN-001, is a clinical-stage anti-IGF-1R monoclonal antibody in development for thyroid eye disease (TED). Viridian is headquartered in Boulder, Colorado , with research and development operations in Waltham, Massachusetts.
treatment   antibody  

add to watch list Paper trade email alert is off

nasdaq:XOMA XOMA Corporation

XOMA | News | $24.97 1.55% 1.52% 17K twitter stocktwits trandingview |
Health Technology
(0.0% 1d) (-1.5% 1m) (29.6% 1y) (0.0% 2d) (0.0% 3d) (-0.4% 7d) (NaN% volume)
Earnings Calendar: 2024-03-07
Market Cap: $ 290,526,325
http://www.xoma.com
 Sec Filling | Patents | 10 employees


(US) XOMA Corp. engages in the discovery and development of therapeutics derived from platform of antibody technologies. Its products includes X358, X213, X129, and gevokizumab. The company was founded by Patrick J. Scannon in 1981 and is headquartered in Emeryville, CA.
antibody  

add to watch list Paper trade email alert is off

nasdaq:XNCR Xencor, Inc.

XNCR | $18.385 -2.98% -3.07% 830K twitter stocktwits trandingview |
Health Technology
(0.0% 1d) (-16.2% 1m) (-32.7% 1y) (0.0% 2d) (0.0% 3d) (-5.2% 7d) (-8.69% volume)
Earnings Calendar: 2024-02-22
Market Cap: $ 1,123,696,201
http://www.xencor.com
 Sec Filling | Patents | 166 employees


(United States) Xencor, Inc. engages in the development of engineered monoclonal antibody therapeutics to treat severe and life-threatening diseases. Its proprietary technology platform, XmAb, is used to create next-generation antibody product candidates designed to treat autoimmune and allergic diseases, cancer, and other conditions. The company was founded by Bassil I. Dahiyat and Stephen L. Mayo in August 1997 and is headquartered in Monrovia, CA.
cancer   antibody   autoimmunity   monoclonal antibodies  

add to watch list Paper trade email alert is off

nasdaq:VINC Vincera Pharma Inc

VINC | $0.8475 -5.83% -6.19% 350K twitter stocktwits trandingview |

(0.0% 1d) (-85.8% 1m) (-5.0% 1y) (0.0% 2d) (0.0% 3d) (9.2% 7d) (-60.7% volume)
Earnings Calendar:
Market Cap: $ 18,147,847
https://vincerx.com
 Sec Filling | Patents | 28 employees


Vincerx Pharma (Vincerx) is a recently formed clinical-stage life sciences company focused on leveraging its extensive development and oncology expertise to advance new therapies intended to address unmet medical needs for the treatment of cancer. Vincerx’s executive team has assembled a management team of biopharmaceutical experts with extensive experience in building and operating organizations that develop and deliver innovative medicines to patients. Vincerx’s current pipeline is derived from an exclusive license agreement with Bayer and includes a clinical-stage and follow-on small molecule drug program and a preclinical stage bioconjugation/next-generation antibody-drug conjugate platform. The company intends to develop multiple products through clinical proof-of-concept and potentially through Accelerated Approval in the United States.
cancer   treatment   antibody   molecule drugs  

add to watch list Paper trade email alert is off
Your Today's Watch List
Sign in to create a watchlist
Gainers vs Losers
67% 33%

Top 10 Gainers
AGBA | News | $1.26 215.0% 68.25% 130M twitter stocktwits trandingview |
Finance
EGOX | $0.0515 43.06% 30.1% 330M twitter stocktwits trandingview |

OLB 4 | $0.33 -14.95% 25.53% 840K twitter stocktwits trandingview |
Technology Services
NVFY | $2.77 31.28% 23.83% 33M twitter stocktwits trandingview |
Consumer Durables
ZCMD | $1.87 28.97% 22.46% 31M twitter stocktwits trandingview |
Commercial Services
RCON | $0.1112 13.01% 21.28% 1.7M twitter stocktwits trandingview |
Distribution Services
INSG | $3.03 25.21% 20.13% 330K twitter stocktwits trandingview |
Electronic Technology
GCTK | $0.8191 22.25% 18.2% 190K twitter stocktwits trandingview |
Manufacturing
WLGS | $0.59 18.0% 17.9% 2.3M twitter stocktwits trandingview |

ASNS | $0.828 21.75% 17.86% 18K twitter stocktwits trandingview |

Last 48 Hours Insiders Buying
RXO P 200000 | $19.37 2.32% 0.0% 1M twitter stocktwits trandingview |
n/a
 | 23:00
RKT P 380 | $11.68 1.3% 0.17% 1.9M twitter stocktwits trandingview |
Finance
 | 22:30
HROW P 29400 | $10.43 -3.87% -4.03% 680K twitter stocktwits trandingview |
Health Technology
 | 22:30
BCDA P 2750 | $0.377 -1.4% 97K twitter stocktwits trandingview |
Health Technology
 | 22:00
RMCF | $3.67 3.38% 3.27% 11K twitter stocktwits trandingview |
Consumer Non-Durables
 | 20:10
12 months watchlist earnings calendar